Back to GetFilings.com



Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

|X| Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                    For quarterly period ended December 31, 2003

[  ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

  For transition period from _______________ to ______________

Commission File Number:    0-16594

     
  MEDICAL TECHNOLOGY SYSTEMS, INC.  

  (Exact Name of Registrant as Specified in Its Charter)  


  Delaware    59-2740462  
 

  (State or Other Jurisdiction of   (I.R.S. Employer  
   Incorporation or Organization)   Identification No.)  


  12920 Automobile Boulevard, Clearwater, Florida   33762  
 

  (Address of Principal Executive Offices)   (Zip Code)  

     
  727-576-6311  
 
 
  (Registrant's Telephone Number, Including Area Code)  

     
     
 
 
  (Former Name, Former Address and Former Fiscal Year,
if changed since last report)
 


            Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.   |X|   Yes      [  ]    No

             Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    [  ]   Yes      [X]    No

             As of February 12, 2004, the registrant had 4,717,987 shares of common stock, $.01 par value per share, issued and outstanding.


MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES

Index

    Page  
     
Part I - Financial Information  
     
  Item 1. Financial Statements      
       
    Condensed Consolidated Balance Sheets - December 31, 2003 and March 31, 2003   1  
     
    Condensed Consolidated Statements of Earnings - Three and Nine Months Ended December 31, 2003 and 2002   2  
     
    Condensed Consolidated Statements of Changes in Stockholders' Equity - Nine Months Ended December 31, 2003   3  
     
    Condensed Consolidated Statements of Cash Flows - Nine Months Ended December 31, 2003 and 2002   4  
       
    Notes to Condensed Consolidated Financial Statements   5 - 13  
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   14 - 20  
       
Item 3. Quantitative and Qualitative Disclosures About Market Risk   20  
       
Item 4. Controls and Procedures   20  
       
Part II - Other Information  
     
       
Item 6. Exhibits and Reports on Form 8-K   22  
     
  Signatures   23  

i.


Table of Contents

PART 1 — FINANCIAL INFORMATION

Item 1. Financial Statements

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands)

ASSETS

December 31, March 31,
2003 2003


(Unaudited)  
         
Current Assets:                
     Cash     $ 245     $ 395    
     Accounts Receivable, Net     5,180       4,756  
     Inventories       3,630       3,080    
     Prepaids and Other       404       76    
     Deferred Tax Benefits      1,291       1,124    


     Total Current Assets      10,750       9,431    
Property and Equipment, Net       3,939       3,023    
Other Assets, Net       3,562       2,774    
Deferred Tax Benefits       1,169       2,155    


Total Assets     $ 19,420     $ 17,383    




LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:                    
     Current Maturities of Long-Term Debt     $ 567     $ 1,461    
     Accounts Payable and Accrued Liabilities       2,613       3,506    


     Total Current Liabilities       3,180       4,967    
Long-Term Debt, Less Current Maturities       9,323       7,023    


Total Liabilities       12,503       11,990    


Stockholders' Equity:    
     Common Stock       45       44    
     Preferred Stock       1       1    
     Capital In Excess of Par Value       11,897       11,881    
     Accumulated Deficit       (4,698 )     (6,205 )  
     Treasury Stock       (328 )     (328 )  


     Total Stockholders' Equity       6,917       5,393    


     Total Liabilities and Stockholders' Equity     $ 19,420     $ 17,383    


The accompanying notes are an integral part of these financial statements.

1


Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES CONDENSED
CONSOLIDATED STATEMENTS OF EARNINGS

(In Thousands; Except Earnings Per Share Amounts)

(Unaudited)

Three Months Ended Nine Months Ended
December 31, December 31,


2003 2002 2003 2002




Revenue:                    
      Net Sales     $ 9,582   $ 7,694   $ 24,613   $ 21,447  
Costs and Expenses:    
      Cost of Sales       5,684     4,573     14,905     13,112  
      Selling, General and Administrative       2,023     1,822     5,301     4,834  
      Depreciation and Amortization       282     243     867     679  




Total Costs and Expenses       7,989     6,638     21,073     18,625  




Operating Profit       1,593     1,056     3,540     2,822  
Other Expenses    
      Interest Expense       221     219     630     668  
      Amortization of:    
          Financing Costs       128     89     299     178  
          Original Issue Discount       62     62     186     127  




Total Other Expenses       411     370     1,115     973  
Income Before Income Taxes       1,182     686     2,425     1,849  
Income Tax Expense       448     261     918     699  




Net Income       734     425     1,507     1,150  
Non-Cash Constructive Dividend Related to    
      Beneficial Conversion Feature of Convertible    
          Preferred Stock       0     0     0     347  
Convertible Preferred Stock Dividends       55     55     165     113  




Net Income Available to Common Stockholders     $ 679   $ 370   $ 1,342   $ 690  




Net Income Per Basic Common Share     $ 0.13   $ 0.07   $ 0.27   $ 0.15  




Net Income Per Diluted Common Share     $ 0.10   $ 0.06   $ 0.20   $ 0.12  




Weighted Average Shares - Basic       5,045     4,936     5,005     4,744  




Weighted Average Shares Outstanding - Diluted       6,937     6,054     6,796     5,694  




The accompanying notes are an integral part of these financial statements.

2


Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
NINE MONTHS ENDED DECEMBER 31, 2003
(In Thousands)
(Unaudited)


  Common Stock   Preferred Stock   Capital            
  $.01 Par Value   $.001 Par Value   In Excess           Total
 
 
  of Par   Accumulated   Treasury   Stockholder's
  Shares   Amount   Shares   Amount   Value   Deficit   Stock   Equity
 
 
 
 
 
 
 
 
                     
Balance, March 31, 2003   4,393,623   $ 44   2,000   $ 1   $ 11,881     $ (6,205 )   $ (328 )   $ 5,393  
                     
Stock Options Exercised   120,287    1         159              160   
                     
Convertible Preferred Stock Dividend                 (165 )              (165 )
                     
Currency Exchange Gain                 22                   22  
                     
Net Income for Nine Months Ended December 31, 2003                       1,507          1,507  
 
 
 
 
 
 
 
 
Balance, December 31, 2003   4,513,910   $ 45   2,000   $ 1   $ 11,897     $ (4,698 )   $ (328 )   $ 6,917  
 
 
 
 
 
 
 
 


The accompanying notes are an integral part of these financial statements.


3


Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)

  Nine Months Ended
  December 31,

  2003   2002
 
 
       
Operating Activities                  
    Net Income     $ 1,507     $ 1,150  
 
 
    Adjustments to Reconcile Net Income to Net Cash    
        Provided by Operating Activities:    
         Reserve for Obsolete Inventory       28       47  
         Amortization of Deferred Financing Costs       299       179  
         Amortization of Original Issue Discount       186       127  
         Depreciation and Amortization       867       681
         Income Tax Expense       819       699
         (Increase) Decrease in:    
            Accounts Receivable       (424 )     (916 )
            Inventories       (420 )     (223 )
            Prepaids and Other       (328 )     (63 )
         Increase (Decrease) in:    
            Accounts Payable and Accrued Liabilities       (545 )     396  
 
 
    Total Adjustments       482       927  
 
 
    Net Cash Provided by Operations       1,989       2,077  
 
 
Investing Activities    
    Expended for Property and Equipment       (1,234 )     (742 )
    Expended for Product Development       (320 )     (384 )
    Expended for Patents and Other Assets       (87 )     (52 )
 
 
    Net Cash (Used) by Investing Activities       (1,641 )     (1,178 )
 
 
Financing Activities    
    Payments on Notes Payable and Long-Term Debt       (1,424 )     (12,089 )
    Advances (Paydowns) on Revolving Line of Credit       932       3,445  
    Borrowing on Term Loans and Subordinated Notes       0       6,700  
    Issuance of Convertible Preferred Stock       0       2,000  
    Exercise of Stock Options       159       0  
    Expended for Financing Costs       0       (1,130 )
    Dividends on Convertible Preferred Stock       (165 )     (113 )
 
 
    Net Cash (Used) by Financing Activities       (498 )     (1,187 )
 
 
Net (Decrease) in Cash       (150 )     (288 )
Cash at Beginning of Period       395       410  
 
 
Cash at End of Period     $ 245     $ 122  
 
 

The accompanying notes are an integral part of these financial statements.

Supplemental Disclosure of Cash Flow Information

December     31, 2003
     Non-Cash Financing Activities – The Company purchased $199,000 in equipment and financed the purchase with a capital lease obligation.

December 31, 2003
      Non-Cash Financing Activities – See Notes F, G, I and M.

4


Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED DECEMBER 31, 2003

NOTE  A – BASIS OF PRESENTATION

        The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three- and nine-month periods ended December 31, 2003 are not necessarily indicative of the results that may be expected for the year ended March 31, 2004. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2003.

        The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, MTS Packaging Systems, Inc. (“MTS Packaging”) and MTS Packaging Systems International, Ltd. (“MTSPI”). All other subsidiaries of the Company did not have operations during the nine-month periods ended December 31, 2003 and 2002.

NOTE B — INVENTORIES

        The components of inventory consist of the following:

  December 31,   March 31,
  2003   2003
 
 
  (In Thousands)
  
Raw Materials     $ 2,002     $ 1,547  
Finished Goods and Work in Progress       1,840       1,716  
Less:  Inventory Valuation Allowance       (212 )     (183 )
 
 
      $ 3,630     $ 3,080  
 
 

NOTE C – EARNINGS PER SHARE

         Net Income per common share is computed by dividing net income available to common shareholders by the basic and diluted weighted average number of shares of common stock outstanding. The number of shares of common stock, for purposes of the basic earnings per share computation, include 566,517 shares that could result from the exercise of warrants exercisable at $.01 per share by the holder of the warrants (see Note G). For diluted weighted average shares outstanding, the Company used the treasury stock method to calculate the common stock equivalents that the stock options and warrants would represent. In addition, for diluted weighted average shares outstanding, the convertible preferred stock has been treated as if it had been converted into common stock on the date of issuance.

5


Table of Contents

        The following table sets forth the computation of income per basic and diluted common share:

  Three Months Ended   Nine Months Ended  
 
 
 
  December 31,   December 31,   December 31,   December 31,  
  2003   2002   2003   2002  
 
 
 
 
 
  (In Thousands; Except Per Share Amounts)
  
Numerator:                    
 Net Income     $ 734   $ 425   $ 1,507   $ 1,150  
   Minus:    
      Constructive Dividend Related to Beneficial    
        Conversion Feature of the Convertible    
           Preferred Stock       0     0     0     347  
       Convertible Preferred Stock Dividend       55     55     165     113  




Net Income Available to Common Stockholders    $ 679   $ 370   $ 1,342   $ 690  




Denominator:  
   Weighted Average Shares Outstanding - Basic       5,045     4,936     5,005     4,744  
   Add: Effect of Dilutive Warrants and Options       1,045     271     944     371  
   Effect of Conversion of Convertible Preferred Stock into Common Stock       847     847     847     579  




   Weighted Average Shares Outstanding - Diluted       6,937     6,054     6,796     5,694  




Income Per Common Share – Basic     $ 0.13   $ 0.07   $ 0.27   $ 0.15  




Income Per Common Share – Diluted     $ 0.10   $ 0.06   $ 0.20   $ 0.12  





        Certain provisions of the warrants and the terms of the convertible preferred stock issued in June 2002 may result in the issuance of additional shares at some future date if certain events occur. Since these events have not yet occurred, and therefore the number of additional shares is not known, no additional shares have been included in the earnings per share calculation (see Note I).

NOTE D – STOCK BASED COMPENSATION

        The Company follows only the disclosure provisions of SFAS No. 123, Accounting for Stock-Based Compensation (SFAS 123), which establishes a fair value based method of accounting for stock-based employee compensation plans; however, the Company has elected to account for its employee stock compensation plans using the intrinsic value method under Accounting Principles Board Opinion No. 25, with pro forma disclosures of net earnings and earnings per share as if the fair value based method of accounting defined in SFAS 123 had been applied. The Company amortizes compensation costs related to the pro forma disclosure using the straight-line method over the vesting period of the employees’ common stock options. If compensation cost for the Company’s stock option plan had been determined based on the fair value at the grant dates for stock-based employee compensation arrangements consistent with the method required by SFAS 123, the Company’s net income and net income per common share would have been the pro forma amounts indicated below:

6


Table of Contents

  Three Months Ended   Nine Months Ended
 
 
  December 31,   December 31,   December 31,   December 31,
  2003   2002   2003   2002
 
 
 
 
  (In Thousands; Except Per Share Amounts)
  
Net Income Available to Common Shareholders as Reported     $ 679     $ 370     $ 1,342     $ 690  
  
Less:                        
    Stock Based Employee Compensation Cost Under the Fair                        
           Value Based Method, Net of Related Tax Effect       137       188       378       392  
 
 
 
 
  
Net Income Proforma     $ 542     $ 182     $ 964     $ 298  
 
 
 
 
  
Net Income Per Common Share, Basic as Reported    $ 0.13     $ 0.07     $ 0.27     $ 0.15  
  
Net Income Per Common Share, Basic Proforma     $ 0.11     $ 0.04     $ 0.19     $ 0.06  
  
Net Income Per Share, Diluted as Reported     $ 0.10     $ 0.06     $ 0.20     $ 0.12  
  
Net Income Per Share, Diluted Proforma     $ 0.08     $ 0.03     $ 0.14     $ 0.05  
  
For Basic Income Per Share - Weighted Average Shares       5,045       4,936       5,005       4,744  
  
For Diluted Income Per Share - Weighted Average Shares     6,937       6,054       6,796       5,694  


NOTE  E – REVENUE RECOGNITION

        The Company recognizes revenue when products are shipped and title transfers. However, revenue related to the sale of OnDemand® machines is recognized upon installation and acceptance of the machine by the customer in accordance with the terms of the purchase agreement. Revenue includes certain amounts invoiced to customers for freight and handling charges. The Company excludes the actual cost of freight and handling incurred from net sales and includes these costs in cost of sales.

        During the quarter ended September 30, 2003, the Company reclassified, into cost of sales, approximately $180,000 of freight costs incurred in the quarter ended June 30, 2003 that had been improperly offset against revenue for freight billed to customers. In addition, the appropriate reclassification was made to the second quarter ended September 30, 2002 financial statements in the amount of $127,000. The reclassifications did not result in a change in gross profit or net income for the three or nine months ended December 31, 2003 or 2002.

7


Table of Contents

NOTE  F – RESEARCH AND DEVELOPMENT AND PRODUCT DEVELOPMENT

        The Company expenses product research and development costs as incurred. The Company incurred approximately $136,000 and $119,000 during the nine months ended December 31, 2003 and 2002, respectively, for research and development costs.

        All costs incurred subsequent to the completion of research and development activities associated with the product’s hardware components and the software components achievement of technological feasibility are capitalized until the product is available for general release to customers. The Company initially classifies the construction costs of the first units produced for commercial use as product development costs prior to transferring these costs to inventory. During the nine months ended December 31, 2003, the Company transferred approximately $92,000 from product development costs to inventory. The Company capitalized approximately $68,000 of product development costs in the three months ended December 31, 2003 compared with $125,000 in the comparable period the prior year and $320,000 in the nine months ended December 31, 2003 compared with $384,000 in the comparable period the prior year.

        Product development costs are generally amortized on a straight-line basis over a five (5) year period. Amortization expense related to product development costs was $24,000 in the three months ended December 31, 2003 compared with $28,000 in the prior year and $184,000 in the nine months ended December 31, 2003 compared with $130,000 in the prior year.

        At December 31, 2003 and March 31, 2003, the Company’s capitalized product development costs included its new OnDemand product and versions thereof, which represented $1,718,000 and $1,428,000, respectively, of the total capitalized product development costs (see Note L).

NOTE  G – LONG-TERM DEBT

  December 31,   March 31,
  2003   2003
 
 
  (In Thousands)
    
Revolving Line of Credit due June 26, 2005 plus interest payable at 1% above the prime rate (5% at December 31, 2003).   $ 4,396     $ 3,465  
    
Bank Term Loan payable in monthly installments of $83,333 plus interest at 2.25% above the prime rate                
      (6.25% at December 31, 2003) and fully repaid in January 2004.     153       1,250  
    
Bank Term Loan payable in monthly installments of $11,667 plus interest at 1.25% above the prime rate                
      (5.25% at December 31, 2003) through June 2007.     490       595  
    
Note Payable to related party (see Note M) payable in monthly installments of $28,785 including interest at 6.25% through July 2008.     1,368       0  
    
Subordinated Note – Face amount of $4,000,000, less unamortized original issue discount of $865,000, due                
      June 26, 2007 plus interest payable monthly at 14%.     3,135       2,949  
    
Other Notes and Agreements     348       225  
 
 
Total Long-Term Debt     9,890       8,484  
Less Current Portion     (567 )     (1,461 )
 
 
LONG-TERM DEBT DUE AFTER 1 YEAR   $ 9,323     $ 7,023  

8


Table of Contents

        In June 2002, the Company repaid the entire amount, $11,310,000, of its bank term loan with the proceeds of a new revolving line of credit, term loans, a subordinated note and convertible preferred stock. The revolving line of credit allows for borrowing of up to $5,000,000 based upon advance rates that are applied to the Company’s eligible accounts receivable and inventory. At December 31, 2003, there was approximately $4.4 million borrowed and an additional approximately $600,000 available on the revolving line of credit. Interest is payable on the revolving line of credit monthly based on the average unpaid balance at the prime rate plus 1.0%.

        One term loan in the amount of $700,000 is repayable in equal monthly installments over a five (5) year term, plus interest at the prime rate plus 1.25%. Another term loan in the amount of $2,000,000 is repayable in equal monthly installments over two (2) years plus interest at the prime rate plus 2.25% and is subject to an excess cash flow payment provision. The Company and its lender agreed that the excess cash flow payment that was due on July 1, 2003, approximately $673,000, would be paid in equal monthly installments beginning August 1, 2003 and ending in January 2004, and as a result, the entire original amount of this term loan will be paid at that date.

        The subordinated note in the amount of $4,000,000 is repayable in five (5) years with interest only, at 14%, payable monthly until the maturity of the note. The subordinated note is secured by a second lien on all of the assets of the Company. In addition, the subordinated note holders were issued 566,517 warrants to purchase common stock exercisable for ten (10) years at $.01 per share (subject to certain antidilution provisions) (see Note I). The relative value of the warrants, and certain embedded features of the warrants, were recorded as part of the stockholders’ equity and reduced the carrying amount of the subordinated note as an original issue discount. The original issue discount is being amortized over the five (5) year term of the subordinated note. Amortization expense related to the original issue discount was $62,000 and $186,000 for the three and nine months ended December 31, 2003.

        The terms of the warrant agreement contain certain antidilution provisions and also contain a make-whole provision that obligates the Company to pay certain amounts to the holders of the warrants if they do not ultimately receive an amount equal to the price per share of the common stock on the date they exercise their right to purchase the common shares that underlie the warrants. The warrant agreement also contains a provision that may obligate the Company to pay certain amounts to the holders of the warrants in the event there is a change in control of the voting common stock of the Company, if there is a sale of the Company, or if there is a public offering of the Company’s common stock. In the event the Company is required to make payments to the holders of the warrants, it may elect to issue additional warrants in lieu of cash payment. The maximum number of shares that the Company may be required to issue is 12,500,000.

        The revolving line of credit and bank term loans are collateralized by a first security interest in all of the assets of the Company.

        The bank term loans also contain provisions that require the Company to maintain certain financial ratios and minimum stockholders’ equity levels of the greater of $4,600,000 or 95% of the stockholders equity at the end of the previous fiscal year. In addition, certain provisions limit the amount of capital expenditures that the Company can make each year. The Company was in compliance with all provisions of the loan agreements at January 31, 2004.

NOTE  H – CONTINGENCIES

        In November 1998, MTL, a discontinued operation, received a refund request in the amount of $1.8 million from Medicare Program Safeguards (“MPS”). MTL disputed the refund request in its response to MPS in December 1998. To date, MTL has not received any further correspondence from MPS regarding this matter.

9


Table of Contents

        The Company is involved in certain claims and legal actions arising in the ordinary course of business including the matter referred to above. There can be no assurances that these matters will be resolved on terms acceptable to the Company. In the opinion of management, based upon advice of counsel and consideration of all facts available at this time, the ultimate disposition of these matters are not expected to have a material adverse effect on the financial position, results of operations or liquidity of the Company.

NOTE  I – STOCKHOLDER EQUITY

        In June 2002, the Company issued subordinated notes to an investor (see Note G). As part of the consideration for the notes, the investor received 566,517 warrants to purchase common stock exercisable at $.01 per share for ten (10) years.

        Also in June 2002, the Company issued 2,000 shares of convertible preferred stock at $1,000 per share. The holders of the convertible preferred stock are entitled to receive quarterly dividends at the rate of 11% per annum. The dividends are payable in cash or shares of convertible preferred stock at the Company’s option and are cumulative. Through the period ended December 31, 2003, all dividends due in the amount of approximately $55,000 were paid in cash. The preferred stock is convertible into 847,457 shares of the Company’s common stock at $2.36 per share. On the date the convertible preferred stock was issued, the fair market value of the Company’s common stock was $2.77 per share based upon the closing bid on the OTC Bulletin Board. The difference between the fair market value of the shares and the conversion price of the convertible preferred stock represented a constructive dividend to the holders of the preferred stock in the amount of $347,000 (see Note C). The Company followed the accounting prescribed in EITF 98-5 and EITF 00-27 for the recording of the convertible preferred stock and the constructive dividend.

        The terms of the warrant and convertible preferred stock agreements contain certain antidilution provisions and also contain a make-whole provision that obligates the Company to pay certain amounts to the holders of the warrants and convertible preferred stock if they do not ultimately receive an amount equal to the price per share of the common stock on the date they exercise their right to purchase the common shares that underlie the warrants or convert the preferred stock into common stock. The warrant agreement also contains a provision that may obligate the Company to pay certain amounts to the holders of the warrants in the event there is a change in control of the voting common stock of the Company, if there is a sale of the Company, or if there is a public offering of the Company’s common stock.

        The value of the warrants was determined as of the date of issuance using the Black-Scholes options-pricing model. In addition, an independent third party has estimated the value of certain embedded features contained in the warrant agreement and registration rights agreement between the Company and the warrant holder (a “make-whole” and “claw-back” feature that obligated the Company to pay additional amounts, in cash or additional shares at the option of the Company, if certain events occur in the future). Using the relative value of the debt ($4,000,000), warrants ($1,564,000) and the warrant’s embedded features ($233,000), the Company recorded the value of the warrants and the warrant’s embedded features as part of its stockholders equity, in accordance with EITF 00-19, and reduced the carrying amount of the debt as an original issue discount.

        The make-whole provision and certain antidilution provisions also represent a contingent beneficial conversion feature of the convertible preferred stock. The effect of this feature may result in the issuance of additional shares at some future date; however, since the issuance of these shares is contingent on future events, the effect of this feature will be recorded at the time the events occur.

10


Table of Contents

        In the event the Company is required to make payments to the holders of the warrants and/or preferred stock, it may elect to issue additional warrants and/or preferred stock in lieu of a cash payment. The make-whole provision and other provisions of the warrant agreement and convertible preferred stock agreement provide for a maximum of 12,500,000 shares that may be issued pursuant to those provisions.

        The Company has determined the value of the warrants and the make-whole and other provisions of the warrants and has recorded this amount as a component of its stockholders’ equity. This amount, $1,240,000 also represents the original issue discount that will be amortized over the five-year term of the subordinated note.

        The Company also issued, to its financial advisors, 125,000 warrants to purchase common stock as part of the fees related to the above referenced financing. The warrants are fully exercisable for five (5) years at $1.50 per share. The value of these warrants, $324,000, was determined based upon the value of the Company’s common stock on the date the warrants were issued. The Company recorded the value of the warrants as a component of its financing costs incurred (see Note J).

NOTE  J – FINANCING COSTS

        The Company incurred approximately $1,458,000 of financing costs during the twelve months ended March 31, 2003, including the value of the warrants issued to the Company’s financial advisors related to obtaining certain financing described in Notes G and I. The financing costs were allocated between the components of the financing that represented debt and equity. The financing costs that were allocated to the debt proceeds, $1,090,000, have been recorded as other assets and will be amortized over the repayment term of the various loans and notes. The financing costs that were allocated to the equity proceeds, $368,000, have been recorded as a reduction of the equity proceeds. There were no additional financing costs incurred during the nine-month period ending December 31, 2003. Amortization expense related to the financing costs that was allocated to the debt was $128,000 and $299,000 for the three and nine months ended December 31, 2003, respectively.

NOTE  K – RECENT NEW ACCOUNTING PRONOUNCEMENTS

        In May 2003, SFAS 150, “Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity” was issued. This statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liability and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of those instruments were previously classified as equity. The Company has reviewed the effect that SFAS 150 has on certain financial instruments issued in June 2002 (see Notes G and I) and has determined that these financial instruments are properly classified in its financial statements as of December 31, 2003.

11


Table of Contents

NOTE  L – OTHER ASSETS

        Other assets consists of the following:

  Amortization        
  Period  December 31,  March 31,  
  (Years)  2003  2003  
 
 
 
 
     (In Thousands)  
        
Product Development  (see Note F)    5   $ 2,250     $ 1,941    
          Less:  Accumulated Amortization           (702     (518 )  
 
 
 
       $ 1,548    $ 1,423   
 
 
 
        
Patents (See Note M)     5 - 17  $ 2,365    $ 1,229   
          Less:   Accumulated Amortization        (967     (808 )  
 
 
 
        $ 1,398    $ 421   
 
 
 
        
Financing Costs  (see Note J)    3 - 5  $ 1,110    $ 1,110   
          Less:  Accumulated Amortization           (570     (271 )  
 
 
 
        $ 540    $ 839   
 
 
 
        
Other    5  $ 288    $ 201   
          Less:  Accumulated Amortization          (212     (110 )  
 
 
 
        $ 76    $ 91   
 
 
 
Total Other Assets, Net       $ 3,562    $ 2,774   
 
 
 

        All of the Company’s intangible assets are pledged as collateral on bank notes.

NOTE  M – RELATED PARTY TRANSACTIONS

        On July 28, 2003, the Company entered into an Asset Purchase Agreement with the Siegel Family Trust (the “Trust”) to purchase the rights to certain proprietary technology that had previously been available to the Company through a license agreement between the Company and the Trust. The purchase price of the rights was $1,480,000. As part of the agreement, the Trust agreed to forgive the royalties of $348,000, that were accrued and unpaid on July 28, 2003, and terminated the license agreement. The purchase price will be paid to the Trust in the form of a promissory note that is payable in sixty (60) monthly payments of $28,785, beginning on August 1, 2003, including interest at the rate of 6.25%. In order to assist the Company in determining the appropriate value of the rights to the proprietary technology, the Board of Directors formed a special committee comprised of three outside independent directors. The special committee engaged an independent third party to conduct an appraisal of the value of the rights. The Company reduced the purchase price of the rights by the amount of the unpaid royalties and recorded the resulting amount as patents. The patents will be amortized over a five-year period, which represents the remaining life of the patents related to these rights.

12


Table of Contents

NOTE  N – COMPENSATION MATTERS

        In July 2003, the Company entered into new employment agreements with its Chief Executive Officer (CEO) and Chief Financial Officer (CFO) that expire on March 31, 2008 and March 31, 2006, respectively. All amounts that may be earned by the CEO and CFO are payable in cash and do not provide the CEO or CFO with an election to receive any portion of the amounts earned in the form of discounted common stock of the Company in lieu of cash.

        In July 2003, the Company and its CEO agreed to terminate, effective April 1, 2003, an Executive Stock Appreciation Rights and a Non-Qualified Stock Option Agreement (SAR) that was entered into in 1995. The agreement provided the CEO with an SAR equal to 3.25% of the incremental increase in the aggregate value of the Company’s common stock each successive year. The agreement also allowed the CEO to receive all amounts owed pursuant to the agreement in the form of discounted common stock of the Company in lieu of cash.

13


Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FOR THE NINE MONTHS ENDED DECEMBER 31, 2003


ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

        This Form 10-Q contains forward-looking statements within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Additional written or oral forward-looking statements may be made by the Company from time to time, in filings with the Securities and Exchange Commission or otherwise. Statements contained herein that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions described above. Forward-looking statements may include, but are not limited to, projections of revenues, income or losses, capital expenditures, plans for future operations, the elimination of losses under certain programs, financing needs or plans, compliance with financial covenants in loan agreements, plans for sale of assets or businesses, plans relating to products or services of the Company, assessments of materiality, predictions of future events and the effects of pending and possible litigation, as well as assumptions relating to the foregoing. In addition, when used in this discussion, the words “anticipates”, “estimates”, “expects”, “intends”, “believes”, “plans” and variations thereof and similar expressions are intended to identify forward-looking statements.

        Forward-looking statements are inherently subject to risks and uncertainties, some of which can be predicted or quantified based on current expectations. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. Statements in Quarterly Reports, particularly in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Notes to Condensed Consolidated Financial Statements, describe factors, among others, that could contribute to or cause such differences. Other factors that could contribute to or cause such differences include, but are not limited to, unanticipated increases in operating costs, labor disputes, capital requirements, increases in borrowing costs, product demand, pricing, market acceptance, intellectual property rights and litigation, risks in product and technology development and other risk factors detailed in the Company’s Securities and Exchange Commission filings. In particular any comments regarding possible default waivers related to the Company’s loan agreement are forward-looking statements.

        Readers are cautioned not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions of these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unexpected events.

Operations

        The Company has continued to experience growth in revenue derived from its disposable punch card product lines primarily due to (1) increased penetration of independent pharmacies throughout the country and (2) the aging demographics of the U.S. population. Independent pharmacies are those that are not affiliated with pharmacies that are national in scope, but rather rely on the relationships they have with nursing homes and assisted living facilities in a small geographic region.

        As the population ages, the number of nursing home and assisted living facility residents grows, which benefits our entire customer base and, in turn, us. In addition, our revenue growth has been enhanced by increased sales of the machines the Company manufactures and sells to its customers, including our new OnDemand® machines.

        Although competitive pricing issues related to the disposable punch card products arise from time to time, the Company relies heavily on the relationships it builds with customers, which are centered around our complete medication packaging system that includes the machines, as well as the disposables in order to offset competitive pricing pressures.

14


Table of Contents

        Although the cost of raw materials used to manufacture the disposable punch cards has risen during the nine months ended December 31, 2003 as compared with the equivalent period in the previous fiscal year, the Company has been successful in maintaining the relationship between its selling prices and direct cost of materials by adjusting prices where appropriate and developing efficiencies by adding new manufacturing equipment that produces cards and blisters. These efficiencies have also offset direct labor cost increases.

        Overhead costs incurred in manufacturing have risen approximately 11% in the nine months ended December 31, 2003 from approximately $2.6 million to approximately $2.9 million compared to the same period in the prior fiscal primarily due to costs added to properly supervise and warranty the OnDemand product line. The Company expects this trend will continue for the remaining portion of fiscal 2004 and for at least some period of fiscal year 2005 as the OnDemand product line generates more customer interest and subsequent revenue.

        Direct selling costs declined to $1.5 million for the nine months ended December 31, 2003 compared to $1.6 million for the same period in the prior fiscal year because the Company has not added significantly to the sales and customer service support staff. However, marketing costs have increased over the same period in the prior fiscal year, from approximately $327,000 to approximately $493,000, as more resources are dedicated to improving product awareness in existing markets, such as skilled nursing and new markets, such as assisted living. Also, it has been necessary to add technical support personnel to assist in the installation and user training of OnDemand machines. The Company expects that selling and marketing costs, as well as OnDemand support costs, will continue to rise as it attempts to reach new markets for its disposable products and additional OnDemand machine sales are realized.

        Administrative costs have risen approximately 13% in the first nine months ended December 31, 2003 compared to the same period in the prior fiscal year from approximately $2.8 million to approximately $3.3 million. The increase is primarily due to costs that have been added to support the operations in the United Kingdom and personnel related expenses including employee benefit costs.

Liquidity

        Cash flow from operations has been sufficient in the first nine months ended December 31, 2003 to fund the necessary capital expenditures and product development projects that are underway. The overall revolving line of credit limit and the borrowing base availability limitations have been sufficient to support the increases in both accounts receivable and inventory that have resulted from increased revenue. As of January 2, 2004, the Company has completely repaid one of its senior term loans. We expect to examine several options that may be available to us to restructure or retire all or part of the existing subordinated debt that carries a significantly higher interest rate. We do not carry significant cash balances because our excess cash is used to reduce the balance on our revolver and thereby providing additional borrowing availability. We view our borrowing availability as our cash reserve. As we look forward, we believe that it may be necessary to adjust the overall limit on our revolving line of credit to provide adequate capital to fund our working capital needs. We intend to address that issue during our fourth fiscal quarter of this year or the first quarter of next fiscal year.

ESTIMATES AND CRITICAL ACCOUNTING POLICIES

        The preparation of the Company’s unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and revenues and expenses for the respective period-ended for such statements. The determination of estimates requires the use of judgment because future events and their affect on the Company’s operations cannot be determined with absolute certainty. Actual results typically differ from these estimates in some fashion, and at times, these variances may be material to the Company’s financial statements. Management continually evaluates its estimates and assumptions, which are based on historical experience and other factors that are believed to be reasonable under these circumstances. These estimates and the Company’s actual results are subject to the risk factors listed above under this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Nevertheless, management of the Company believes the following items involve a higher degree of complexity and, judgment and therefore, has commented on these items below.

15


Table of Contents

Valuation of Accounts Receivable at December 31, 2003

        The Company’s allowance for doubtful accounts of $181,000 at December 31, 2003 is based on management’s estimates of the credit-worthiness of its customers, current economic conditions and historical information. In the opinion of management, the Company’s allowance for doubtful accounts is believed to be an amount sufficient to respond to normal business conditions. Historically, the levels of recorded bad debt expense and write-offs have not been material to the Company’s financial statements. Should business conditions deteriorate or any large customer default on its obligations to the Company, this allowance may need to be significantly increased, which would have a negative impact upon the Company’s operations.

Inventory Obsolescence Valuation Allowance

        The Company’s allowance for inventory obsolescence and slow moving inventory is reviewed on a monthly basis. The Company reviews various information related to the age and turnover of specific inventory items to assist in its assessment. In the opinion of management, the valuation allowance is believed to be sufficient to absorb the ultimate obsolescence of certain inventory as they may occur. The inventory obsolescence valuation allowance was $211,000 at December 31, 2003.

Self-Insurance Plan Reserve

        The Company established a reserve for unpaid medical claims of $89,000 at December 31, 2003. Management reviews claims history information provided to it by the third-party administrator of the self insured plan on a regular basis and believes that the reserve is sufficient to respond to the claims that may be incurred by the participants in the plan.

Deferred Tax Asset Valuation Allowance

        The Company’s deferred tax asset is comprised primarily of a tax loss carryforward. The Company believes that it is more likely than not that the income tax benefits associated with the tax loss carryforward will be realized in the future. Management bases its belief, in part, on the historical profitability of its operations and its expectations that profitable operations will continue in the future. Based upon these expectations regarding the realization of the tax benefits, management has not established a valuation allowance for its deferred tax asset.

Impairment Valuations

        On a quarterly basis, management assesses the composition of the Company’s assets and liabilities, as well as the events that have occurred and the circumstances that have changed since the most recent fair value determination. If events occur or circumstances change that would more likely than not reduce the fair value of the related asset or liability below its carrying amount, the related asset or liability would be tested for impairment.

        The Company evaluates the recoverability of its long-lived assets whenever circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered include current operating results, trends and anticipated undiscounted future cash flows. An impairment loss is recognized to the extent the sum of discounted (using the Company’s incremental borrowing rate) estimated future cash flows (over a period ranging from generally four to ten years) expected to result from the use of the asset is less than the carrying value. Management of the Company believes no impairment existed for any of the periods presented.

16


Table of Contents

Product Development

        All costs incurred subsequent to the completion of research and development activities associated with a product’s hardware components and the software components achievement of technological feasibility are capitalized until the product is available for general release to customers. Product development costs are generally amortized over a five-year period beginning on the date the product is released for sale to customers. On a quarterly basis, the Company reviews the viability and recoverability of these project costs.

Estimated Liabilities

        The Company makes a number of estimates in the ordinary course of business. Historically, past changes to these estimates have not had a material impact on the Company’s financial condition. However, circumstances could change, which would alter future financial information based upon a change in estimated-vs.-actual results.

        The Company is subject to various matters of litigation in the ordinary course of business. As the outcome of any litigation is unknown, management estimates the potential amount of liability, if any, in excess of any applicable insurance coverage, based on historical experience and/or the best estimate of the matter at hand. Significant changes in estimated amounts could occur. To date, the Company has not had to pay any legal settlements in excess of existing insurance coverage.

Warranty

        The Company establishes a reserve for warranty costs it may incur during the warranty period that is provided for in the OnDemand machine sales agreements with its customers. To date, warranty costs have not been material.

RESULTS OF OPERATIONS

Three Months Ended December 31, 2003 and 2002

        Net sales for the three months ended December 31, 2003 increased 24.6% to $9.6 million from $7.7 million during the same period in the prior fiscal year. Net sales increased primarily as a result of an increase in the amount of disposable punch cards and machines sold to new and existing customers. In addition, revenue associated with the sale of OnDemand machines increased in the three months ended December 31, 2003 compared to the same period in the prior year. Average selling prices for disposable products were slightly higher during the third quarter of fiscal 2004 compared to the same period in the prior fiscal year. The volume of disposable cards and machines is currently anticipated to continue to grow as a result of the addition of new customers in existing and new markets.

        Cost of sales for the three months ended December 31, 2003 increased 23.9% to $5.7 million from $4.6 million during the same period in the prior year. Cost of sales as a percentage of sales decreased to 59.4% from 59.7% during the same period in the prior fiscal year. Cost of sales as a percentage of sales decreased on disposable punch cards because the volume of punch cards increased, and therefore, absorbed more factory overhead costs. However, overhead costs associated with the OnDemand product partially offset the decreased cost of sales on disposable punch cards.

        Selling, general and administration expenses for the three months ended December 31, 2003 increased 11.1% to $2.0 million from $1.8 million in the prior year primarily due to increased marketing expenses and support costs associated with the OnDemand machine product line. In addition, operating costs in the United Kingdom were higher than in the prior fiscal year primarily because of the addition of personnel and facilities to accommodate the growth in business activity there.

17


Table of Contents

        Depreciation and amortization expenses for the three months ended December 31, 2003 increased 16.0% to $282,000 from $243,000 during the same period in the prior fiscal year. The increase is primarily a result of the fact that the Company began amortizing the capitalized product development costs associated with the OnDemand machine during the second quarter of the prior fiscal year and began amortizing the cost of the proprietary technology acquired in the second quarter of this fiscal year. In addition, depreciation expense related to capital expenditures made during the prior fiscal year contributed to the increase.

        Interest expense for the three months ended December 31, 2003 increased 1% to $221,000 from $219,000 during the same period in the prior fiscal year. The increase results from an overall increase in debt resulting from the purchase of proprietary technology from a related party as well as higher borrowing on the revolving line of credit.

        Other expenses related to the June 2002 refinancing of the Company’s long-term debt (see Note G) were $190,000 and $151,000 during the three months ended December 31, 2003 and 2002, respectively. These expenses resulted from the amortization of certain costs associated with the financing of approximately $128,000 and $89,000, respectively, as well as the amortization of the original issue discount associated with the subordinated debt portion of the financing of approximately $62,000 in both periods.

        Income tax expense increased 71% to $448,000 during the three months ended December 31, 2003 compared to $261,000 during the same period in the prior fiscal year. The increase results from income tax expense associated with higher net income. There was no significant change in the effective tax rates for the respective periods.

Nine Months Ended December 31, 2003 and 2002

        Net sales for the nine months ended December 31, 2003 increased 14.9% to $24.6 million from $21.4 million during the same period in the prior fiscal year. Net sales increased primarily as a result of an increase in the amount of disposable punch cards and machines sold to new and existing customers. Prices for disposable products were slightly higher during the first nine months of fiscal 2004 compared to the same period in the prior fiscal year. In addition, the Company realized an increase in revenue associated with sale of OnDemand machines in the nine months ended December 31, 2003 compared to the same period in the prior fiscal year. The volume of disposable cards and machines is currently anticipated to continue to grow as a result of the addition of new customers in existing and new markets.

        Cost of sales for the nine months ended December 31, 2003 increased 13.7% to $14.9 million from $13.1 million during the same period in the prior fiscal year. Cost of sales as a percentage of sales decreased to 60.6% from 61.2% during the same period in the prior fiscal year. Gross margins associated with disposable products increased in the nine months ended December 31, 2003, however overhead costs associated with the OnDemand product partially offset the decreased cost of sales on disposable punch cards.

        Selling, general and administration expenses for the nine months ended December 31, 2003 increased 10.4% to $5.3 million from $4.8 million in the same period during the prior fiscal year primarily due to increased personnel benefit costs, costs associated with the Company’s operations in the United Kingdom, increased marketing costs and support costs for the OnDemand machine product line.

        Depreciation and amortization expenses for the nine months ended December 31, 2003 increased 27.7% to $867,000 from $679,000 during the same period in the prior fiscal year. The increase is primarily a result of the fact that the Company began amortizing the capitalized product development costs associated with the OnDemand machine during the second quarter of the prior fiscal year and began amortizing the cost of the proprietary technology acquired in the second quarter of this fiscal year. In addition, depreciation expense related to capital expenditures made during the prior fiscal year contributed to the increase.

18


Table of Contents

        Interest expense for the nine months ended December 31, 2003 decreased 5.7% to $630,000 from $668,000 during the same period in the prior year. Although the level of borrowing on the revolving line of credit increased during the nine months ended December 31, 2003 and the Company incurred more debt when it purchased proprietary technology from a related party, the principal payments made in the nine months ended December 31, 2003 on the senior term loans coupled with lower prime rates caused total interest expense to be lower in the nine months ended December 31, 2003 compared to the same period in the prior fiscal year.

        Other expenses related to the June 2002 refinancing of the Company’s long-term debt (see Note G) increased to $485,000 during the nine months ended December 31, 2003 compared to $305,000 during the same period in the prior fiscal year. These expenses resulted from the amortization of certain costs associated with the financing of approximately $299,000 and $178,000, respectively, as well as the amortization of the original issue discount associated with the subordinated debt portion of the financing of approximately $186,000 and $127,000, respectively. These expenses increased because the financing was completed at the end of the first quarter of the prior fiscal year 2003, and therefore, there was no expense recorded in the first quarter of the prior fiscal year.

        Income tax expense increased 31.3% to $918,000 during the nine months ended December 31, 2003 compared to $699,000 in the same period in the prior fiscal year. The increase results from income tax expense associated with higher net income. There was no significant change in the effective tax rates for the respective periods.

LIQUIDITY AND CAPITAL RESOURCES

        During the nine months ended December 31, 2003, the Company had net income of $1,507,000 compared to net income of $1,150,000 during the same period in the prior fiscal year. Cash provided by operations was $1,989,000 during the nine months ended December 31, 2003 compared to $2,077,000 provided during the same period in the prior fiscal year. The Company had working capital of $7,570,000 at December 31, 2003.

        The decrease in cash provided by operating activities during the nine months ended December 31, 2003 compared to the same period in the prior fiscal year was due to an increase in inventory primarily related to OnDemand machine component parts, and deposits provided to subcontract manufacturers of OnDemand machines.

        Investing activities used $1,641,000 during the nine months ended December 31, 2003 compared to $1,178,000 during the same period in the prior fiscal year. The increase results primarily from an increase in expenditures made for new disposable punch card manufacturing equipment.

        Financing activities used $498,000 during the nine months ended December 31, 2003 compared to $1,187,000 during the same period in the prior fiscal year. The decrease results primarily from the fact that during the same period in the prior year, the Company incurred certain costs to obtain capital to refinance its long-term debt.

        The Company’s short-term and long-term liquidity is primarily dependent on its ability to generate cash flow from operations. Inventory levels may change significantly if the Company is successful in selling its OnDemand machines. Increases in net sales may result in corresponding increases in accounts receivable. Cash flow from operations and borrowing availability on the revolving line of credit is anticipated to support an increase in accounts receivable and inventory.

        The Company has new product development projects underway, principally new versions of its OnDemand machine, that are expected to be funded by cash flow from operations. These projects are monitored on a regular basis to attempt to ensure that the anticipated costs associated with them do not exceed the Company’s ability to fund them from cash flow from operations and other sources of capital.

        There was $3.5 million borrowed and approximately an additional $1.0 million available on the Company’s revolving line of credit at January 28, 2004 based upon eligible accounts receivable and inventory. In addition, the Company had $1,000,000 available on its capital equipment line of credit.

19


Table of Contents

        The revolving line of credit, term loans and subordinated notes each contain financial covenants that, among other things, requires the Company to maintain certain financial ratios, limits the amount of capital expenditures and requires the Company to obtain the lenders approval for certain matters. The Company was in compliance with all provisions of the loan agreements at January 28, 2004.

        The Company believes that the cash generated from operations during this fiscal year, and amounts available on its revolving line of credit, are expected to be sufficient to meet its capital expenditures, product development, working capital needs and the principal payments required by its term loan agreements.

Item 3.   Quantitative and Qualitative Disclosures About Market Risk

        There have been no material changes in our market risk during the nine months ended December 31, 2003. Market risk information is contained under the caption “Quantitative And Qualitative Disclosures About Market Risk” of our annual report on Form 10-K for the fiscal year ended March 31, 2003 and is incorporated herein by reference.

Item 4.   Controls and Procedures

        We carried out an evaluation required by Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934 (the “Evaluation”), under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15 and 15d-15 promulgated under the Securities Exchange Act of 1934 (“Disclosure Controls”). Although we believe that our pre-existing Disclosure Controls, including our internal controls, were adequate to enable us to comply with our disclosure obligations, as a result of such Evaluation, we implemented minor changes, primarily to formalize, document and update the procedures already in place. Based on the Evaluation, our CEO and CFO concluded that, subject to the limitations noted below, our Disclosure Controls are effective in timely alerting them to material information required to be in our periodic Securities and Exchange Commission reports.

Changes in Internal Controls

        There has not been any change in our internal control over financial reporting identified in connection with the Evaluation that occurred during the quarter ended December 31, 2003 that has materially affected or is reasonably likely to materially affect, those controls.

Limitations on the Effectiveness of Controls

        Our management, including our CEO and CFO, does not expect that our Disclosure Controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

20


Table of Contents

        The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events occurring. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

CEO and CFO Certifications

        Exhibits 31.1 and 31.2 are Certifications of the CEO and the CFO, respectively. The Certifications are required in accord with Section 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”). This Item of this report, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

21


Table of Contents

PART II — OTHER INFORMATION

Item  6.     Exhibits and Reports on Form 8-K

    
  (a) Exhibits  
    
   31.1 Certification of the President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
    
   31.2 Certification of the Vice President and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
    
   32.1 Certification of the President and Chief Executive Officer Pursuant to 18 U.S.C. §1350.
    
  32.2 Certification of the Vice President and Chief Financial Oficer Pursuant to 18 U.S.C. §1350.
    
  (b) Reports on Form 8-K
    
  On February 5, 2004, we filed a Current Report on Form 8-K in which we disclosed under Items 7 and 12 a press release announcing the results of operations for the third quarter and nine months ended December 31, 2003.

22


Table of Contents

Signatures

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  MEDICAL TECHNOLOGY SYSTEMS, INC.
   
Date:   February 17, 2004   By: /s/ Michael P. Conroy  

   
 
    Michael P. Conroy  
    Vice President and Chief Financial Officer  

   
Date:   February 17, 2004   By: /s/ Mark J. Connolly  

   
 
    Mark J. Connolly  
    Principal Accounting Officer and Controller